Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In Brief: Merck Aggrastat

Executive Summary

Merck Aggrastat: FDA's Cardiovascular & Renal Drugs Advisory Committee will discuss NDAs 20-912 and 20-913 for Merck's tirofiban April 10. The applications cover two indications: use in combination with heparin for patients with unstable angina or non-Q-wave myocardial infarction to prevent cardiac ischemic events and use in patients with coronary ischemic syndromes undergoing percutaneous translumenal coronary angioplasty or atherectomy to prevent cardiac ischemic complications related to abrupt closure of the treated coronary artery...
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS031870

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel